Enrolled
n=245

Completed Week 12
n=153 (62.4%)

Discontinued, n=92 (37.6%)
Subject withdrew consent, n=47 (51.1%)
Lack of efficacy, n=25 (27.2%)
Other, n=7 (7.6%)
Lost to follow up, n=6 (6.5%)
Adverse event, n=4 (4.3%)
Protocol violation, n=2 (2.2%)
Death, n=1 (1.1%)

Completed Week 64
n=79 (32.2%)

Discontinued, n=74 (30.2%)
Lack of efficacy, n=23 (31.1%)
Subject withdrew consent, n=23 (31.1%)
Protocol violation, n=9 (12.2%)
Adverse event, n=7 (9.5%)
Lost to follow up, n=7 (9.5%)
Other, n=4 (5.4%)
Death, n=1 (1.4%)